AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...

Physicians recommend that patients with chronic obstructive pulmonary disease (COPD) quit smoking and use steroids, antibiotics and other drugs to manage the sometimes debilitating symptoms. However, ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

Learn how personalized exercise routines can transform your COPD journey, enhance resilience, and improve your quality of ...

The growing prevalence of COPD among women can be attributed to a combination of biological, environmental, and societal ...

Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...